Ivermectin, a drug originally designed for treating parasitic infections, has become a focal point of intense public, medical, and legislative interest in the United States in 2025. What started as off-label use during the COVID-19 pandemic has evolved into a complex landscape defined by shifting usage patterns, evolving regulations, and legislative movements across states. This blog dives deep...